Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Grand Valley Oncology
mi
from
Grand Junction, CO
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Grand Valley Oncology
mi
from
Grand Junction, CO
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Mountain States Tumor Institute
mi
from
Boise, ID
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute
mi
from
Boise, ID
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Mountain States Tumor Institute - Fruitland
mi
from
Fruitland, ID
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute - Fruitland
mi
from
Fruitland, ID
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Mountain States Tumor Institute - Meridian
mi
from
Meridian, ID
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute - Meridian
mi
from
Meridian, ID
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Mountain States Tumor Institute - Nampa
mi
from
Nampa, ID
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute - Nampa
mi
from
Nampa, ID
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Mountain States Tumor Institute-Twin Falls
mi
from
Twin Falls, ID
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute-Twin Falls
mi
from
Twin Falls, ID
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Deaconess Clinic Downtown
mi
from
Evansville, IN
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Deaconess Clinic Downtown
mi
from
Evansville, IN
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Chancellor Center for Oncology
mi
from
Newburgh, IN
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Chancellor Center for Oncology
mi
from
Newburgh, IN
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Broadlawns Medical Center
mi
from
Des Moines, IA
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Broadlawns Medical Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Heartland Regional Medical Center
mi
from
Saint Joseph, MO
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Heartland Regional Medical Center
mi
from
Saint Joseph, MO
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital Oklahoma City
mi
from
Oklahoma City, OK
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital Oklahoma City
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Saint Charles Health System
mi
from
Bend, OR
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Saint Charles Health System
mi
from
Bend, OR
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Clackamas Radiation Oncology Center
mi
from
Clackamas, OR
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Clackamas Radiation Oncology Center
mi
from
Clackamas, OR
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Providence Oncology and Hematology Care Southeast
mi
from
Clackamas, OR
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Providence Oncology and Hematology Care Southeast
mi
from
Clackamas, OR
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Bay Area Hospital
mi
from
Coos Bay, OR
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Bay Area Hospital
mi
from
Coos Bay, OR
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Providence Newberg Medical Center
mi
from
Newberg, OR
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Providence Newberg Medical Center
mi
from
Newberg, OR
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Providence Portland Medical Center
mi
from
Portland, OR
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Providence Saint Vincent Medical Center
mi
from
Portland, OR
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Providence Saint Vincent Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Farmington Health Center
mi
from
Farmington, UT
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Farmington Health Center
mi
from
Farmington, UT
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Providence Regional Cancer System-Aberdeen
mi
from
Aberdeen, WA
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Providence Regional Cancer System-Aberdeen
mi
from
Aberdeen, WA
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
PeaceHealth Saint Joseph Medical Center
mi
from
Bellingham, WA
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
PeaceHealth Saint Joseph Medical Center
mi
from
Bellingham, WA
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Providence Regional Cancer System-Centralia
mi
from
Centralia, WA
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Providence Regional Cancer System-Centralia
mi
from
Centralia, WA
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center-Edmonds
mi
from
Edmonds, WA
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center-Edmonds
mi
from
Edmonds, WA
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Providence Regional Cancer Partnership
mi
from
Everett, WA
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Providence Regional Cancer Partnership
mi
from
Everett, WA
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Swedish Cancer Institute-Issaquah
mi
from
Issaquah, WA
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Swedish Cancer Institute-Issaquah
mi
from
Issaquah, WA
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Kadlec Clinic Hematology and Oncology
mi
from
Kennewick, WA
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Kadlec Clinic Hematology and Oncology
mi
from
Kennewick, WA
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Providence Regional Cancer System-Lacey
mi
from
Lacey, WA
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Providence Regional Cancer System-Lacey
mi
from
Lacey, WA
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
PeaceHealth Saint John Medical Center
mi
from
Longview, WA
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
PeaceHealth Saint John Medical Center
mi
from
Longview, WA
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Pacific Gynecology Specialists
mi
from
Seattle, WA
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Pacific Gynecology Specialists
mi
from
Seattle, WA
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center-Ballard Campus
mi
from
Seattle, WA
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center-Ballard Campus
mi
from
Seattle, WA
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center-First Hill
mi
from
Seattle, WA
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center-First Hill
mi
from
Seattle, WA
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center - Cherry Hill
mi
from
Seattle, WA
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center - Cherry Hill
mi
from
Seattle, WA
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Providence Regional Cancer System-Shelton
mi
from
Shelton, WA
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Providence Regional Cancer System-Shelton
mi
from
Shelton, WA
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Rockwood Clinic Cancer Treatment Center-Valley
mi
from
Spokane Valley, WA
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Rockwood Clinic Cancer Treatment Center-Valley
mi
from
Spokane Valley, WA
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Rockwood Cancer Treatment Center-DHEC-Downtown
mi
from
Spokane, WA
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Rockwood Cancer Treatment Center-DHEC-Downtown
mi
from
Spokane, WA
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Rockwood North Cancer Treatment Center
mi
from
Spokane, WA
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Rockwood North Cancer Treatment Center
mi
from
Spokane, WA
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
PeaceHealth Southwest Medical Center
mi
from
Vancouver, WA
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
PeaceHealth Southwest Medical Center
mi
from
Vancouver, WA
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Providence Saint Mary Regional Cancer Center
mi
from
Walla Walla, WA
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Providence Saint Mary Regional Cancer Center
mi
from
Walla Walla, WA
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Providence Regional Cancer System-Yelm
mi
from
Yelm, WA
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Providence Regional Cancer System-Yelm
mi
from
Yelm, WA
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Integrity Oncology PLLC-Collierville
mi
from
Collierville, TN
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Integrity Oncology PLLC-Collierville
mi
from
Collierville, TN
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Washington
mi
from
Seattle, WA
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Veterans Administration Medical Center.
mi
from
Salisbury, NC
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Veterans Administration Medical Center.
mi
from
Salisbury, NC
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Desert West Surgery
mi
from
Las Vegas, NV
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Desert West Surgery
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Marshfield Clinic - Chippewa Center
mi
from
Chippewa Falls, WI
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Marshfield Clinic - Chippewa Center
mi
from
Chippewa Falls, WI
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Marshfield Clinic - Ladysmith Center
mi
from
Ladysmith, WI
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Marshfield Clinic - Ladysmith Center
mi
from
Ladysmith, WI
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Marshfield Clinic Minocqua Center
mi
from
Minocqua, WI
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Marshfield Clinic Minocqua Center
mi
from
Minocqua, WI
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Marshfield Clinic Stevens Point Center
mi
from
Stevens Point, WI
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Marshfield Clinic Stevens Point Center
mi
from
Stevens Point, WI
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Marshfield Clinic - Wausau Center
mi
from
Wausau, WI
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Marshfield Clinic - Wausau Center
mi
from
Wausau, WI
Click here to add this to my saved trials
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated:  12/31/1969
Marshfield Clinic - Weston Center
mi
from
Weston, WI
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Enrolling
Updated: 12/31/1969
Marshfield Clinic - Weston Center
mi
from
Weston, WI
Click here to add this to my saved trials